Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales	[1]	$ 1,174.5	$ 1,217.0
CSCA
Disaggregation of Revenue [Line Items]
Net sales	[2]	581.8	601.6
CSCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[2]	132.6	141.5
CSCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[2]	100.3	92.2
CSCA | Infant nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[2]	96.0	103.4
CSCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[2]	88.8	93.7
CSCA | Smoking cessation
Disaggregation of Revenue [Line Items]
Net sales	[2]	66.8	65.9
CSCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[2]	19.6	26.3
CSCA | Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales	[2]	3.4	3.0
CSCA | Other CHCA
Disaggregation of Revenue [Line Items]
Net sales	[2],[3]	74.3	75.6
CSCI
Disaggregation of Revenue [Line Items]
Net sales		350.8	377.8
CSCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales		95.7	98.7
CSCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales		81.5	89.7
CSCI | Personal care and derma-therapeutics
Disaggregation of Revenue [Line Items]
Net sales		66.0	75.6
CSCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales		29.8	33.2
CSCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales		26.7	28.1
CSCI | Other CHCI
Disaggregation of Revenue [Line Items]
Net sales	[4]	51.1	52.5
RX
Disaggregation of Revenue [Line Items]
Net sales		$ 241.9	$ 237.6

[1] Derived from the location of the entity that sells to a third party.

[2] Includes net sales from our OTC contract manufacturing business.

[3] Consists primarily of branded OTC, diabetic care, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

[4] Consists primarily of liquid licensed products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.